Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored cocktail aims to wipe out CLL in young High-Risk patients

NCT ID NCT05478512

Ongoing Disease control Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a personalized approach for young adults (18-65) with high-risk chronic lymphocytic leukemia (CLL) who haven't been treated before. Patients first get a combination of venetoclax and obinutuzumab, then their treatment is adjusted based on whether cancer cells remain. If no cancer is detected, they take venetoclax alone for a short time; if cancer remains, they add zanubrutinib. The goal is to achieve undetectable minimal residual disease, meaning no cancer cells can be found, and tailor therapy to each patient's needs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
venetoclax, obinutuzumab, and zanubrutinib
What this could lead to
If successful, this could offer a personalized treatment approach that reduces or eliminates cancer cells in young high-risk CLL patients, potentially delaying or avoiding long-term therapy.
What could go wrong
This is a small phase 2 trial with only 78 participants, so results may not apply to all patients. The treatment involves multiple drugs with side effects, and some patients may still need ongoing therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA HIGH RISK CLL

Contacts and locations

Locations

  • Ematologia AO di Perugia

    Perugia, Italy

  • Ematologia AOU Careggi

    Florence, Italy

  • Ematologia AOUS - Policlinico S. M. alle Scotte

    Siena, Italy

  • Ematologia IRST D.Amadori

    Meldola, Italy

  • Ematologia Ospedale Infermi

    Rimini, Italy

  • Ematologia Ospedale S.M. delle Croci

    Ravenna, Italy

  • Ematologia Policlinico Gemelli

    Roma, Italy

  • Ematologia Policlinico Umberto I

    Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.